Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Healthcare Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Sernova Corp > SVA POTENTIAL TO HAVE $96 Million in Cash
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(19)
•••
Comment by donkeyfeatherson May 21, 2022 5:42pm
231 Views
Post# 34700647

RE:RE:RE:SVA POTENTIAL TO HAVE $96 Million in Cash

RE:RE:RE:SVA POTENTIAL TO HAVE $96 Million in CashI would assume that if a competitor held stock in SVA it would be through a proxy (so it appears as indirect investment).  And this type of situation where a publically traded company gets manipulated on the path to overcoming the goals of those who do not want to have their business model disrupted, needs both the great science people, and even greater business acumen (sniff out and get rid of shmoozers who make us look amateurish).  I'm hoping that EVOTEC's vote of confidence is not just a vote (and cheque).  I see this partnership and an uplisting as a signal that we might finally be graduating into more than road shows and slide decks.  We might even start looking like Pro's. (Please!!!)
DF
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities